Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Douglas A StewartGary Calandra

Abstract

Phase I pharmacokinetic (PK) and pharmacodynamic (PD) studies in healthy volunteers demonstrated that plerixafor (AMD3100), a CXCR4 antagonist, administered either alone or with granulocyte colony-stimulating factor (G-CSF), resulted in dose-dependent mobilization of CD34(+) cells in the peripheral blood. The purpose of this study was to evaluate the safety and the PK and PD of plerixafor with G-CSF in patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). This was a phase II, open-label, single-arm study conducted in 2 centers in Canada. Patients aged 18 to 70 years with NHL or MM eligible for autologous transplantation were eligible. A total of 22 patients (8 with NHL and 14 with MM) were enrolled in the study. The patients were given G-CSF (10 microg/kg/day subcutaneously [s.c.]) for 4 days in the morning and plerixafor 240 microg/kg s.c. on the evening before each day of apheresis. Apheresis was initiated 10 to 11 hours after each evening dose of plerixafor and after the morning dose of G-CSF. This regimen was repeated for up to 5 days or until > or = 5 x 10(6) CD34(+) cells/kg were collected. The objectives were to determine the safety and efficacy of plerixafor in patients with NHL and MM, and the PK and PD o...Continue Reading

References

Mar 23, 2004·Bone Marrow Transplantation·T KuittinenE Jantunen
Feb 3, 2005·Stem Cells and Development·Anand P Jillella, Celalettin Ustun

❮ Previous
Next ❯

Citations

Aug 30, 2011·Bone Marrow Transplantation·Ş M Bakanay, T Demirer
Mar 7, 2012·Proceedings of the National Academy of Sciences of the United States of America·Graeme O'BoyleJohn A Kirby
Jun 13, 2009·Blood·Camille N Abboud
Apr 7, 2011·Core Evidence·Huda Salman, Hillard M Lazarus
Mar 23, 2011·Bioanalysis·Lorin K RoskosMeina Liang
Jan 31, 2014·Blood Reviews·Rusudan K Hopman, John F DiPersio
Feb 18, 2016·Bioconjugate Chemistry·Sophie PotyFranck Denat
Aug 13, 2009·Expert Opinion on Therapeutic Targets·Benjamin F Chong, Chandra Mohan
Nov 19, 2010·Expert Review of Hematology·Lloyd E Damon, Lauren E Damon
Jul 20, 2010·British Journal of Haematology·Morie A Gertz
Apr 24, 2010·Pharmacotherapy·Mika R KessansDenise R Kockler
Jun 24, 2015·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Hakan GokerYahya Buyukasik
Apr 29, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ashok SrinivasanWing Leung
Jun 11, 2011·Clinical Lymphoma, Myeloma & Leukemia·Dennis L CooperStuart E Seropian
Sep 15, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ronald MacFarlandGary Calandra
Jun 15, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·R Donald HarveyEdmund K Waller
Jul 9, 2013·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Fanny ChambonJustyna Kanold
Feb 3, 2015·Dalton Transactions : an International Journal of Inorganic Chemistry·Sophie PotyFranck Denat
Sep 1, 2016·Journal of Clinical Apheresis·Lynn D HaynesDixon B Kaufman
Mar 14, 2017·Nature Reviews. Genetics·Joshua Y C Yang, Minnie M Sarwal
Nov 26, 2010·The Annals of Pharmacotherapy·Kelly M GregoryPaul M Armistead
Dec 10, 2009·The Annals of Pharmacotherapy·Lindsay L RosenbeckPatrick J Kiel
Dec 17, 2009·The Annals of Pharmacotherapy·Hye-Yoon ChoiBong Kyu Yoo
Aug 1, 2014·American Journal of Physiology. Renal Physiology·A ZukS Ledbetter
Jan 7, 2020·Expert Opinion on Drug Metabolism & Toxicology·Miao MiaoGuangdi Li
Jul 12, 2019·Blood Advances·Catriona McCallionJohn Burthem
Feb 18, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Sarah E StumpMaurice D Alexander

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.